Dong · BMJ global health 2022 · systematic review and meta-analysis · n=89 studies (158,287 individuals)

Global seroprevalence and sociodemographic characteristics of Borrelia burgdorferi sensu lato in human populations: a systematic review and meta-analysis.

Cited 91 times in the scientific literature.

Level 3 - non-randomized controlled study

Systematic review and meta-analysis of observational seroprevalence studies

PubMed 35697507 · doi:10.1136/bmjgh-2021-007744 · record verified 2026-08-27

What was done

Authors searched PubMed, Embase, Web of Science, and other databases through December 30, 2021, for peer-reviewed observational studies on human *Borrelia burgdorferi* sensu lato (Bb) seroprevalence that reported laboratory detection methods. Risk of bias was evaluated using the Newcastle-Ottawa Quality Assessment Scale. Random-effects meta-analysis and meta-regression were performed to determine pooled global and regional seroprevalence rates and associated demographic and methodological factors.

What was found

Across 89 included studies totaling 158,287 individuals, estimated global Bb seroprevalence was 14.5% (95% CI 12.8% to 16.3%). The highest regional rates were Central Europe (20.7%, 95% CI 13.8% to 28.6%), Eastern Asia (15.9%, 95% CI 6.6% to 28.3%), and Western Europe (13.5%, 95% CI 9.5% to 18.0%). Testing methods lacking Western blot (WB) confirmation showed higher seropositivity detection compared to WB-confirmed methods (OR 1.9, 95% CI 1.6 to 2.2). Higher seropositivity was also observed in individuals with tick bites (18.8%, 95% CI 10.1% to 29.4%), age ≥50 years (12.6%, 95% CI 8.0% to 18.1%), rural residence (8.4%, 95% CI 5.0% to 12.6%), and men (7.8%, 95% CI 4.6% to 11.9%).

Why it matters

This study provides comprehensive global estimates of human exposure to Lyme borreliosis agents and highlights that unconfirmed serological assays substantially inflate seropositivity estimates.

Limits

The primary studies rely on observational designs with variable sampling methods and testing protocols across countries. Seropositivity reflects antibody exposure rather than active infection, and non-standardized assays without Western blot confirmation create a substantial risk of false-positive results.

Cited by